Dow Inc.
DOW
$39.55
+4.05%
Dow Inc. is a diversified global chemicals producer, operating in the Basic Materials sector with a focus on chemicals like polyethylene, ethylene oxide, and silicone rubber for a wide range of consumer and industrial applications. The company is a market leader in several key chemical product lines, established as an independent entity following the DowDuPont merger and subsequent separations. The current investor narrative is dominated by the severe impact of Middle East supply chain disruptions, particularly the closure and subsequent reopening of the Strait of Hormuz, which has caused significant volatility in feedstock costs and petrochemical prices, leading to mixed quarterly results and a debate between near-term operational headwinds and the company's long-term cost-saving initiatives and recovery potential.…
DOW
Dow Inc.
$39.55
Related headlines
Investment Opinion: Should I buy DOW Today?
Rating: Hold. The core thesis is that DOW is a high-risk, high-reward cyclical turnaround story where the powerful technical recovery has largely priced in the near-term optimism, but the fundamental proof of a sustainable margin rebound is still missing, warranting caution.
Supporting evidence includes a deeply discounted valuation (PS of 0.416), a significant +36.85% three-month price rally indicating shifting sentiment, and analyst consensus pointing to a modest +6.6% upside to an implied target of $41.21. However, this is counterbalanced by severe profitability issues (Q4 gross margin of 5.79%, negative FCF), persistent revenue declines (-9.08% YoY), and high financial leverage (D/E of 1.22). The forward PE of 23.16 is rich and demands perfect execution.
The thesis would upgrade to a Buy on concrete evidence of margin recovery, such as two consecutive quarters of gross margin expansion above 10% and a return to positive free cash flow. It would downgrade to a Sell if revenue decline accelerates beyond -10% YoY or if the stock breaks below key technical support at $30, invalidating the recovery trend. Relative to its own distressed history, the stock is fairly valued; relative to a normalized earnings profile, it remains overvalued until profitability is restored.
Sign up to view all
DOW 12-Month Price Forecast
DOW presents a classic 'show me' story at a critical inflection point. The technical breakout and easing geopolitical headwinds provide a compelling narrative for recovery, which is why the stock has rallied powerfully. However, the fundamental picture remains bleak, with no evidence yet that cost initiatives can overcome weak demand. The neutral stance reflects this dichotomy: the risk/reward is balanced, with the base case of a choppy, range-bound recovery being most probable. The stance would upgrade to bullish on confirmation of margin recovery in the next two quarterly reports. It would turn bearish if the stock fails to hold above $35 and the Q2 2026 earnings show no sequential improvement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dow Inc.'s 12-month outlook, with a consensus price target around $51.41 and implied upside of +30.0% versus the current price.
Average Target
$51.41
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$32 - $51
Analyst target range
Analyst coverage consists of 11 firms, with recent institutional ratings showing a mix of actions including upgrades to 'Buy' and 'Overweight' from Citigroup and JP Morgan in March 2026, alongside several 'Neutral' or 'Hold' ratings, indicating a cautiously optimistic but divided sentiment. The consensus recommendation leans neutral-to-bullish, with an average target price implied by estimated metrics; using the estimated EPS average of $1.78 and a forward PE of 23.16, the implied target price is approximately $41.21, suggesting a potential upside of about +6.6% from the current price of $38.66, though a direct average price target is not provided in the data. The target range, inferred from EPS estimates, spans a low of $1.50 to a high of $2.06, translating to a wide price range; the high target likely assumes a successful navigation of supply chain issues, margin recovery, and cyclical uplift, while the low target prices in continued operational challenges and potential recessionary impacts. The recent flurry of rating changes in March 2026, including several upgrades, signals analysts are actively reassessing the story amidst volatile commodity markets, and the wide implied target spread reflects the high uncertainty surrounding the timing and magnitude of a fundamental turnaround.
Bulls vs Bears: DOW Investment Factors
The bull and bear cases for DOW are in sharp tension, with the bulls arguing for a deep-value cyclical recovery play and the bears pointing to a fundamentally broken business model in the near term. The bull side currently has stronger technical and sentiment evidence, driven by a powerful price recovery from the lows and recent analyst upgrades. However, the bear side's evidence is more concrete and current, rooted in catastrophic quarterly financials. The single most important tension in the investment debate is the timing and magnitude of a margin recovery. Bulls bet that easing geopolitical pressures and cost initiatives will swiftly restore profitability, justifying the low PS multiple. Bears contend that demand softness and operational inefficiencies will persist, making the current valuation a value trap rather than an opportunity.
Bullish
- Deep Value PS Ratio at Historical Low: The stock trades at a trailing PS ratio of 0.416, near the very bottom of its historical range. This extreme discount prices in the current cyclical downturn and suggests significant upside potential if the petrochemical cycle turns, as evidenced by the stock's 52-week low of $20.40 and subsequent 90% recovery.
- Strong Technical Momentum and Recovery: The stock is up 36.85% over the past three months and 55.82% over six months, decisively breaking out from its lows. Trading at 90% of its 52-week range ($20.40 to $42.74) signals strong underlying momentum and a shift in market sentiment towards recovery.
- Analyst Upgrades and Positive Forward Outlook: Recent upgrades to 'Buy' and 'Overweight' from major firms like Citigroup and JP Morgan in March 2026 indicate a reassessment of the story. The implied analyst target price of $41.21 offers a +6.6% upside, with a high EPS estimate of $2.06 suggesting a more bullish recovery scenario.
- Geopolitical Risk Premium Easing: The reopening of the Strait of Hormuz in mid-April 2026 removes a major supply chain overhang that crushed margins. This should alleviate feedstock cost volatility and operational disruptions, providing a clearer path for the company's cost-saving initiatives to improve profitability.
Bearish
- Severe Profitability Collapse and Losses: Q4 2025 results showed a catastrophic net loss of -$1.54 billion and a gross margin of only 5.79%, down from 6.91% in Q3. This indicates the company is currently burning cash, with a negative free cash flow of -$2.61 billion TTM, and is not generating sufficient internal funds.
- Persistent Revenue Decline and Demand Softness: Revenue has declined for four consecutive quarters, with Q4 2025 revenue of $9.46B representing a -9.08% YoY drop from $10.41B. This multi-quarter downtrend across all segments points to a challenging cyclical environment and weak end-market demand.
- High Financial Leverage and Weak Balance Sheet: A debt-to-equity ratio of 1.22 indicates a leveraged capital structure. Combined with a negative ROE of -16.39% and deep negative free cash flow, the company's financial risk is elevated, limiting its flexibility to invest or weather a prolonged downturn.
- Valuation Discount Justified by Fundamentals: The low PS ratio of 0.416 is not an anomaly but a reflection of severely deteriorated fundamentals. The forward PE of 23.16, while positive, is high for a cyclical chemicals company and requires flawless execution of a recovery that is not yet evident in the financials.
DOW Technical Analysis
The stock is in a sustained recovery uptrend from its lows, evidenced by a 1-year price change of +29.91%, significantly outperforming the S&P 500's +30.59% by a narrow margin. Currently trading at $38.66, the price sits at approximately 90% of its 52-week range ($20.40 to $42.74), indicating it is near the upper bound of its yearly trading band, which suggests strong momentum but also proximity to a key technical resistance level that could cap further gains. Recent momentum shows a notable divergence, with the stock down -2.42% over the past month against a strong market (SPY +8.7%), yet up a robust +36.85% over the past three months, signaling that the powerful rally from Q1 2026 may be experiencing a short-term consolidation or pullback as it digests gains and contends with fundamental news. Key technical support is anchored at the 52-week low of $20.40, while immediate resistance is at the 52-week high of $42.74; a decisive breakout above $42.74 would confirm the bullish trend's resumption, whereas a failure here could lead to a retest of lower support levels. The stock's volatility, as implied by its significant drawdown of -43.59% and its underperformance relative to the market over the past month, highlights its sensitivity to commodity cycles and geopolitical events, which is critical for risk-aware investors.
Beta
0.49
0.49x market volatility
Max Drawdown
-42.0%
Largest decline past year
52-Week Range
$20-$43
Price range past year
Annual Return
+29.0%
Cumulative gain past year
| Period | DOW Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +12.6% |
| 3m | +45.6% | +2.5% |
| 6m | +65.8% | +4.3% |
| 1y | +29.0% | +28.4% |
| ytd | +63.0% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOW Fundamental Analysis
Revenue trajectory is under significant pressure, with the most recent Q4 2025 revenue of $9.46 billion representing a -9.08% year-over-year decline, continuing a multi-quarter downtrend from $10.43 billion in Q1 2025. The Packaging & Specialty Plastics segment, at $4.74 billion, remains the largest revenue contributor, but all segments are likely feeling the impact of demand softness and supply chain disruptions, indicating a challenging cyclical environment for the investment case. Profitability has deteriorated sharply, with the company reporting a net loss of -$1.54 billion in Q4 2025 and a gross margin of only 5.79%, down from a net income of $62 million and a 6.91% gross margin in Q3 2025; this compression reflects severe margin pressure from input cost volatility and operational inefficiencies, moving the company away from the profitability seen in 2024. The balance sheet shows a debt-to-equity ratio of 1.22, indicating a leveraged capital structure, while free cash flow over the trailing twelve months is deeply negative at -$2.61 billion; the current ratio of 1.97 suggests adequate short-term liquidity, but the negative free cash flow and ROE of -16.39% signal the company is not currently generating sufficient internal cash to fund operations and is reliant on external financing, elevating financial risk.
Quarterly Revenue
$9.5B
2025-12
Revenue YoY Growth
-0.09%
YoY Comparison
Gross Margin
+0.05%
Latest Quarter
Free Cash Flow
$-2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOW Overvalued?
Given the negative trailing Net Income of -$1.54 billion, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.416, while the forward-looking metric, EV-to-Sales, is 1.139; the gap suggests the market is pricing in a modest expectation of sales stabilization or recovery, but the low absolute multiple primarily reflects the company's current lack of profitability and margin compression. Compared to industry averages, specific data is not available in the provided dataset; however, a PS ratio of 0.42 is typically very low for a chemical company, suggesting the market is applying a heavy discount due to the cyclical downturn and recent losses, which may be justified by the current fundamental deterioration but could present a deep-value opportunity if a recovery materializes. Historically, Dow's own PS ratio has fluctuated widely, from a low near 0.42 in the current period to highs above 4.0 in early 2021; the current PS of 0.416 is near the very bottom of its historical range, indicating the stock is being valued as if in a severe trough, which could signal a value opportunity if the cycle turns, but also reflects the market's pessimistic view of near-term fundamentals.
PE
-6.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -133x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe. Dow is currently unprofitable, with a Q4 2025 net loss of -$1.54B and a gross margin compressed to 5.79%. The company is burning cash at a rate of -$2.61B over the trailing twelve months, while carrying significant leverage with a debt-to-equity ratio of 1.22. This creates a dependency on external financing and limits strategic flexibility. Revenue concentration in cyclical petrochemicals, with the Packaging & Specialty Plastics segment contributing roughly half of sales, exposes the company to global industrial demand swings, as seen in the -9.08% YoY revenue decline.
Market & Competitive Risks center on its cyclical nature and valuation. While the PS ratio of 0.416 is low, the forward PE of 23.16 is high and implies the market is pricing in a sharp earnings recovery. If this recovery is delayed, significant multiple compression could occur. The stock has shown high sensitivity to geopolitical events (Middle East disruptions) and commodity prices, as evidenced by its -43.59% max drawdown and recent underperformance (-2.42% vs. SPY +8.7% over 1 month). Competitive pressures in a commoditized industry could prevent margin recovery even if demand stabilizes.
The Worst-Case Scenario involves a prolonged global industrial recession combined with sustained high feedstock costs. This would lead to continued revenue declines, permanent margin impairment, a breach of debt covenants, and a potential dividend cut. In this adverse scenario, the stock could realistically retest its 52-week low of $20.40, representing a downside of approximately -47% from the current price of $38.66. The bear-case analyst EPS low of $1.50, applied to a compressed multiple, could also imply a target in the mid-$20s, suggesting a -30% to -40% downside risk is plausible if the recovery thesis fails.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company is burning cash (-$2.61B TTM) and is leveraged (D/E of 1.22), raising solvency concerns in a prolonged downturn. 2) Operational Risk: Gross margins collapsed to 5.79% in Q4 2025; failure to restore profitability would invalidate the recovery thesis. 3) Cyclical/Macro Risk: Revenue has declined for four straight quarters (-9.08% YoY); a global industrial recession could extend this trend. 4) Geopolitical Risk: The stock has shown extreme sensitivity to Middle East supply chain disruptions, which could re-emerge. The combination of these risks means the potential for permanent capital loss is significant.
The 12-month forecast is bifurcated, with a high degree of uncertainty. The base case (50% probability) sees a range-bound stock between $38 and $42 as the company shows slow, gradual improvement. The bull case (30% probability) targets $45 to $50 on a swift margin recovery and cycle upturn. The bear case (20% probability) warns of a drop to $25-$30 if the recovery fails and financial stress intensifies. The most likely scenario is the base case, which assumes analysts' average EPS estimate of $1.78 is met, implying a target near $41. The key assumption behind this forecast is that the reopening of the Strait of Hormuz provides enough cost relief to halt the margin erosion seen in Q4.
DOW's valuation is a paradox. On a Price-to-Sales basis, it appears deeply undervalued at 0.416, trading near the bottom of its historical range and suggesting the market is pricing in a severe, permanent downturn. However, on a forward earnings basis, it appears overvalued with a forward PE of 23.16, which is high for a cyclical chemicals company and implies the market expects a sharp profit recovery that has not yet materialized. Therefore, the stock is fairly valued relative to its current distressed state but overvalued relative to its near-term earnings power. The market is paying a premium for anticipated recovery, making the valuation highly dependent on future execution.
DOW is a high-risk, potentially high-reward investment that is only a 'good buy' for a specific investor profile. For a risk-tolerant investor seeking a cyclical recovery play, the historically low PS ratio of 0.416 and powerful technical rebound offer compelling entry points on pullbacks. However, the average analyst target implies only +6.6% upside, which is modest given the fundamental risks of continued losses, high debt, and negative cash flow. It is not a good buy for conservative investors or those seeking stable income, as the dividend is at risk if profitability does not recover. A purchase should be conditioned on a belief that the petrochemical cycle is bottoming and that Q2 2026 results will show tangible margin improvement.
DOW is unsuitable for short-term trading due to its high volatility and sensitivity to unpredictable commodity and geopolitical news. It is best approached as a tactical, medium-to-long-term investment for investors with a 12-24 month horizon who are betting on a full cyclical recovery. The stock's high beta nature, lack of near-term earnings visibility, and need for multiple quarters to demonstrate a financial turnaround necessitate patience. A long-term 'buy and hold' approach is only justified if one believes in the secular demand for its chemical products and the company's ability to navigate cycles, which is currently unproven. A minimum holding period of 12-18 months is suggested to allow the recovery thesis to play out or fail.